Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome
Recruiting
Phase 3
Interventional Study
Acute Respiratory Distress Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 178 (estimated)
- Sponsor
- Zhiming Jiang · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Acute respiratory distress syndrome (ARDS) is a clinical syndrome caused by intrapulmonary and/or extrapulmonary causes, characterized by intractable hypoxemia. Studies have shown that the sympathetic nervous system is over-activated in patients with acute respiratory distress syndrome. A large retrospective study showed a reduction in mortality in ARDS patients treated with oral β1 blockers befor…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Meeting the 2012 Berlin diagnostic criteria for acute respiratory distress syndrome;
* Aged between 18-65 years (inclusive);
* 95 times/min ≤ heart rate ≤120 times/min;
* The patient needs to undergo endotracheal intubation mechanical ventilation after condition assessment;
* …
Contacts